TNF-α gene polymorphisms: Association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis

Journal of Investigative Dermatology

Volumn 134, Issue 10, 2014, Pages 2503-2509

  Murdaca, Giuseppe ^a   Gulli, Rossella ^b   Spanò, Francesca ^a   Lantieri, Francesca ^b   Burlando, Martina ^b   Parodi, Aurora ^b   Mandich, Paola ^b   Puppo, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DAS28; DISABILITY INDEX HEALTH ASSESSMENT QUESTIONNAIRE; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE DURATION; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FUNCTIONAL STATUS ASSESSMENT; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MIDDLE AGED; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ANALOG SCALE; ALLELE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; ALLELES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, PSORIATIC; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922394025     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.123     Document Type: Article

References (37)

1. Balding J, Kane D, Livingstone W et al. (2003) Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum 48:1408-13
2. Bowcock AM, Cookson WO (2004) The genetics of psoriasis, psoriatic arthritis, and atopic dermatitis. Hum Mol Genet 13:R43-55
3. Chang J, Girgis L (2007) Clinical use of anti-TNF-alpha biological agents-a guide for GPs. Aust Fam Physician 36:1035-8
4. D'Alfonso S, Momigliano Richiardi P (1996) An intragenic polymorphism in the human tumor necrosis factor alpha (TNFA) chain encoding gene. Immunogenetics 44:321-2
5. Danning CL, Illei GG, Hitchon C et al. (2000) Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 43:1244-56
6. Fabris M, Di Poi E, D'Elia A et al. (2002) Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis. J Rheumatol 29:29-33
7. Gladman DD, Rahman P (2001) Psoriatic arthritis. In: Ruddy S, Harris ED, Sledge CB, Budd RC, Sergent JS eds Kelly's Textbook of Rheumatology. WB Saunders: Philadelphia, 1071-9
8. Gonzalez S, Brautbar C, Martinez-Borra J et al. (2001) Polymorphism in MICA rather than HLA-B/C genes is associated with psoriatic arthritis in the Jewish population. Hum Immunol 62:632-8
9. Gonzalez S, Martinez-Borra J, Lopez-Vazquez A et al. (2002) MICA rather than MICB, TNFa, or HLADRB1 is associated with susceptibility to psoriatic arthritis. J Rheumatol 29:973-8
10. Hamamoto Y, Tateno H, Ishida T et al. (2000) Lack of association between promoter polymorphism of the tumor necrosis factor-alpha gene and psoriatic arthritis in Japanese patients. J Invest Dermatol 115:1162-4
11. Hohler T, Grossmann S, Stradmann-Bellinghausen B et al. (2002) Differential association of polymorphisms in the TNFa region with psoriatic arthritis but not psoriasis. Ann Rheum Dis 61:213-8
12. Höhler T, Kruger A, Schneider PM et al. (1997) A TNF-a promoter polymorphism is associated with psoriasis and psoriatic arthritis. J Invest Dermatol 109:562-5
13. Huizinga TW, Pisetsky DS, Kimberly RP (2004) Associations, populations, and the truth: recommendations for genetic association studies in arthritis and rheumatism. Arthritis Rheum 50:2066-71
14. Ioannidis JP, Ntzani EE, Trikalinos TA et al. (2001) Replication validity of genetic association studies. Nat Genet 29:306-9
15. Kane D, FitzGerald O (2004) Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective. Curr Rheumatol Rep 6:292-8
16. Lee YH, Ji JD, Bae SC et al. (2010) Associations between tumor necrosis factoralpha (TNF-alpha)-308 and-238 G/A polymorphisms and shared epitope status and responsiveness to TNF-alpha blockers in rheumatoid arthritis: a metaanalysis update. J Rheumatol 37:740-6
17. Lin YJ, Chen RH, Wan L et al. (2009) Association of TNF-alpha gene polymorphisms with systemic lupus erythematosus in Taiwanese patients. Lupus 18:974-9
18. Low AS, Gonzalez-Gay MA, Akil M et al. (2002) TNF 489 polymorphism does not contribute to susceptibility to rheumatoid arthritis. Clin Exp Rheumatol 20:829-32
19. Miller SE, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215
20. Moll JMH, Wright V (1973) Familial occurrence of psoriatic arthritis. Ann Rheum Dis 32:181-201
21. Mossner R, Kingo K, Kleensang A et al. (2005) Association of TNF-238 and-308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. J Invest Dermatol 124:282-4
22. Mullighan CG, Fanning GC, Chapel HM et al. (1997) TNF and lymphotoxinalpha polymorphisms associated with common variable immunodeficiency: role in the pathogenesis of granulomatous disease. J Immunol 159:6236-41
23. Murdaca G, Colombo BM, Cagnati P et al. (2012) Update upon efficacy and safety of TNF-a inhibitors. Expert Opin Drug Saf 11:1-5
24. Murdaca G, Colombo BM, Puppo F (2011) Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. Drugs Today (Barc) 47:277-88
25. Murdaca G, Colombo BM, Puppo F (2009) Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol 22:557-65
26. Nishibu A, Oyama N, Nakamura K et al. (2002) Lack of association of TNF-238A and-308A in Japanese patients with psoriasis vulgaris, psoriatic arthritis and generalized pustular psoriasis. J Dermatol Sci 29:181-4
27. O'Rielly DD, Roslin NM, Beyene J et al. (2009) TNF-alpha-308G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics J 9:161-7
28. Partsch G, Steiner G, Leeb BF et al. (1997) Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 24:518-23
29. Prieto-Perez R, Cabaleiro T, Dauden E et al. (2013) Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases. Pharmacogenomics J 13:297-305
30. Purcell S, Neale B, Todd-Brown K et al. (2007) PLINK: a toolset for wholegenome association and population-based linkage analysis. Am J Hum Genet 81:559-75
31. Rahman P, Siannis F, Butt C et al. (2006) TNFa polymorphisms and risk of psoriatic arthritis. Ann Rheum Dis 65:919-23
32. Seitz M,Wirthmü ller U, Mö ller B et al. (2007) The-308 tumour necrosis factoralpha gene polymorphism predicts therapeutic response to TNF alphablockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 46:93-6
33. Taylor PC (2003) Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol 3:323-8
34. Taylor W, Gladman D, Helliwell P et al. (2006) CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665-73
35. Tolusso B, Fabris M, Caporali R et al. (2005) -238 and 489. TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with systemic sclerosis. Immunol Lett 96:103-8
36. van Krugten MV, Huizinga TW, Kaijzel EL et al. (1999) Association of the TNF 489 polymorphism with susceptibility and radiographic damage in rheumatoid arthritis. Genes Immun 1:91-6
37. Vasilopoulos Y, Manolika M (2012) Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in Greek population. Mol Diagn Ther 16:29-34